上海：鼓励及时将创新药械数据提供给商业保险公司作为定价参考

Core Viewpoint - The document outlines measures to promote the high-quality development of commercial health insurance, supporting innovation in the biopharmaceutical industry through enhanced data sharing and collaboration among various stakeholders [1] Group 1: Data Sharing and Collaboration - The measures emphasize upgrading health data sharing capabilities, focusing on deepening the data sharing mechanisms among medical, health insurance, and commercial insurance sectors [1] - It highlights the importance of ensuring data security and privacy while expanding the dimensions and scope of data sharing to support product design, actuarial pricing, and risk assessment for commercial insurance [1] - The establishment of a data cooperation and sharing mechanism is encouraged, utilizing the city's big data center and certified third-party organizations [1] Group 2: Support for Insurance Companies - Insurance companies are supported in accessing historical health data in a secure environment, which aids in collecting and analyzing claims-related diagnostic information and medical expense details [1] - The measures aim to facilitate the development of insurance products tailored for specific groups and risks, enhancing risk prevention strategies [1] - Medical institutions and pharmaceutical companies are encouraged to provide timely information on innovative drugs and devices, including disease applicability and clinical trial data, to commercial insurers for pricing reference [1]